Roche has announced the launch of the Roche Genentech Innovation Center Boston, which will serve as the company’s CVRM hub.
The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback